Piramal Pharma Ltd - Stock Valuation and Financial Performance

BSE: 543635 | NSE: PPLPHARMA | Pharmaceuticals & Drugs | Small Cap

Piramal Pharma Share Price

140.20 1.45 1.05%
as on 15-Apr'24 15:55

DeciZen - make an informed investing decision on Piramal Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation


3. Price Trend

Piramal Pharma stock performance -

mw4me loader
P/E Ratio (SA):
Market Cap:
18,534.5 Cr.
52-wk low:
52-wk high:

Is Piramal Pharma Ltd an attractive stock to invest in?

1. Is Piramal Pharma Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Piramal Pharma Ltd is a below average quality company.

2. Is Piramal Pharma Ltd undervalued or overvalued?

The key valuation ratios of Piramal Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Piramal Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Piramal Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Piramal Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Piramal Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 12.6%7.4%0.9%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2,9393,3403,4433,919
Sales YoY Gr.-13.7%3.1%-
Adj EPS 5.22.9-0.21.2
YoY Gr.--45.1%-106.6%-
BVPS (₹) 40.342.243.148.5
Adj Net
Cash Flow from Ops. 34.724971.5-
Debt/CF from Ops. 4.84.622.8-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANANA3.1%
Adj EPS NANANA-106.6%
Share Price - - - 100.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Sales growth is good in last 4 quarters at 13.21%

Return on Equity has declined versus last 3 years average to 2.60%

Sales growth has been subdued in last 3 years 0.00%

Latest Financials - Piramal Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 1.2 -0.3
TTM Sales (₹ Cr.) 3,919 7,782
BVPS (₹.) 48.5 58.6
Reserves (₹ Cr.) 5,096 6,431
P/BV 2.89 2.39
PE 115.96 0.00
From the Market
52 Week Low / High (₹) 67.88 / 149.00
All Time Low / High (₹) 61.65 / 197.08
Market Cap (₹ Cr.) 18,535
Equity (₹ Cr.) 1,323
Face Value (₹) 10
Industry PE 47.5

Management X-Ray of Piramal Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Piramal Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 2,3202,8653,346
Manufacturing Costs315367426
Material Costs1,2281,5621,768
Employee Cost 395448549
Other Costs 382488602
Operating Profit 61947598
Operating Profit Margin (%) 21.1%14.2%2.8%
Other Income 198225341
Interest 557116
Depreciation 144165192
Exceptional Items 18-15-7
Profit Before Tax 687462124
Tax 1159554
Profit After Tax 57236870
PAT Margin (%) 19.4%11.0%2.0%
Adjusted EPS (₹)
Dividend Payout Ratio (%)0%0%0%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 4,1015,1235,262
Share Capital 9951,1861,193
Reserves 3,1063,9374,068
Minority Interest000
Long Term Debt0477592
Short Term Debt165390720
Trade Payables584647762
Others Liabilities 1,002942960
Total Liabilities 5,8527,5798,296

Fixed Assets

Gross Block2,2603,2253,571
Accumulated Depreciation633786969
Net Fixed Assets1,6272,4392,602
CWIP 121405417
Investments 1,5921,6301,747
Trade Receivables840989910
Cash Equivalents 15213764
Others Assets1,1001,4441,738
Total Assets 5,8527,5798,296

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 3524972
PBT 669477131
Adjustment -3104351
Changes in Working Capital -228-168-50
Tax Paid -95-103-60
Cash Flow From Investing Activity -4,383-1,246-435
Capex -55-231-243
Net Investments -3,710-137-82
Others -618-877-110
Cash Flow From Financing Activity 4,494896290
Net Proceeds from Shares 3,44800
Net Proceeds from Borrowing 0697134
Interest Paid -4-45-101
Dividend Paid 0-50-67
Others 1,050294324
Net Cash Flow 146-100-73
ROE (%)13.947.971.34
ROCE (%)16.219.863.64
Asset Turnover Ratio0.520.510.45
PAT to CFO Conversion(x)0.060.681.03
Working Capital Days
Receivable Days1009897
Inventory Days505169
Payable Days174144145

Piramal Pharma Ltd Stock News

Piramal Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Piramal Pharma on 15-Apr-2024 15:55 is ₹140.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 15-Apr-2024 15:55 the market cap of Piramal Pharma stood at ₹18,534.5.
The latest P/E ratio of Piramal Pharma as of 15-Apr-2024 15:55 is 116.0.
The latest P/B ratio of Piramal Pharma as of 15-Apr-2024 15:55 is 2.89.
The 52-week high of Piramal Pharma is ₹149.0 and the 52-week low is ₹67.88.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Piramal Pharma is ₹3,919 ( Cr.) .

About Piramal Pharma Ltd

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across several global facilities and a global distribution network in hundreds of countries. It includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.

PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The India Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the India consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group.

Business area of the company

The company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across many global facilities and a global distribution network in hundreds of countries. It includes PPS, PCC and the India Consumer Healthcare business, selling over-the-counter products.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.